ConductScience.org, home

Library / Trial comparisons

Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.007360.005510.00984wilsonClinicalTrials.gov
Risk in group 20.00770.00580.0102wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.000339-0.003470.00278newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9560.6361.44logClinicalTrials.gov
Odds ratio, group 1 over group 20.9560.6341.44logClinicalTrials.gov
Number needed to treat, for one fewer death from any cause on Low Molecular Weight Heparin (LMWH)-Enoxaparin than on Acetylsalicylic Acid (ASA)-Aspirin2,950from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Low Molecular Weight Heparin (LMWH)-Enoxaparin
Injection of 30 mg enoxaparin, twice a day via injection~Low Molecular Weight Heparin (LMWH): The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
456,110EG000ClinicalTrials.gov
Group 2Acetylsalicylic Acid (ASA)-Aspirin
Enteral ingestion or administration of 81 mg ASA, twice a day~Acetylsalicylic acid: The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
476,101EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, all-cause mortalityClinicalTrials.gov
Time frame90 daysClinicalTrials.gov

Trial 8

FieldValueSource
TitlePREVENTion of Clot in Orthopaedic TraumaClinicalTrials.gov
NCT numberNCT02984384ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsBlood Clot, TraumaClinicalTrials.gov
InterventionsAcetylsalicylic acid, Low Molecular Weight Heparin (LMWH)ClinicalTrials.gov
Lead sponsorMajor Extremity Trauma Research ConsortiumClinicalTrials.gov
Results first posted2024-05-14ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT02984384?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.